{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":1573,"total_is_capped":false,"direct_labels_cover":19,"predictions_cover":1573,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"d79608c2f8c0","filters":{"venue":"New England Journal of Medicine"}},"results":[{"id":"W2096287682","doi":"10.1056/nejmoa043330","title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma","year":2005,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":21625,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research; Queen's University; University of Calgary; Hôpital Notre-Dame; Western University","funders":"National Cancer Institute","keywords":"Temozolomide; Medicine; Radiation therapy; Concomitant; Glioblastoma; Adjuvant; Adjuvant radiotherapy; Oncology; Internal medicine; Surgery; Cancer research","retraction":null,"screen_n_in":null,"score":{"opus":0.01630284871862668,"gpt":0.2917034007174995,"spread":0.2754005519988728,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004989422,0.000162054,0.0006934247,0.0001857423,0.00004443278,0.000008247439,0.00005745546,0.00005825925,0.0001272198],"category_scores_gemma":[0.0002159726,0.00009239805,0.00009337926,0.00007969051,0.00008651257,0.00006619754,0.000007179757,0.0001501566,0.000001551634],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000129423,"about_ca_system_score_gemma":0.0001439623,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002231362,"about_ca_topic_score_gemma":0.00004371269,"domain_scores_codex":[0.9988657,0.00002960625,0.0005007429,0.0001262728,0.0002825425,0.0001950839],"domain_scores_gemma":[0.9986837,0.0003723097,0.0002522104,0.0001226304,0.0001499033,0.0004192293],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.008490401,0.0002627303,0.01243799,0.00006281215,0.0006667622,0.0007134539,0.001889625,0.00006323982,0.02312384,0.0005358612,0.06405922,0.8876941],"study_design_scores_gemma":[0.3550792,0.01684402,0.01298604,0.0009193463,0.0008590847,0.01257635,0.0002875957,0.001018342,0.007735369,0.0004759967,0.591035,0.0001836432],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.891727,0.02541843,0.0010207,0.08084155,0.0003474329,0.0003651485,0.000003179733,0.00001297107,0.000263586],"genre_scores_gemma":[0.9841111,0.002744316,0.005282193,0.001810729,0.005770077,0.000004522602,0.000002363411,0.00002206427,0.0002526544],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8875104,"threshold_uncertainty_score":0.3767883,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2146264128","doi":"10.1056/nejmoa1504720","title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12000,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Empagliflozin; Medicine; Hazard ratio; Myocardial infarction; Internal medicine; Placebo; Confidence interval; Relative risk; Diabetes mellitus; Stroke (engine); Angina; Type 2 diabetes; Cardiology; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.03667286996223124,"gpt":0.2896293482684484,"spread":0.2529564783062172,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001361217,0.0001271733,0.000715279,0.0002004902,0.000008393732,0.000006139442,0.00005126102,0.000038621,0.00003948493],"category_scores_gemma":[0.0004266667,0.00007527038,0.00008114312,0.0001668377,0.00005852595,0.00007830213,0.00002494927,0.0001594309,0.000003515325],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005590723,"about_ca_system_score_gemma":0.00008935067,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009606587,"about_ca_topic_score_gemma":0.00003169207,"domain_scores_codex":[0.9988003,0.00005835696,0.0003584695,0.0001065406,0.0005067202,0.0001696317],"domain_scores_gemma":[0.9991512,0.00005332831,0.00009333454,0.0001904831,0.0001351986,0.0003764051],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001787485,0.00006794824,0.918018,0.00003954982,0.0008957813,0.000502502,0.0004364275,0.00001265454,0.00001684682,0.00003076572,0.003520293,0.07628046],"study_design_scores_gemma":[0.05833382,0.001807743,0.8552662,0.0002943588,0.001361596,0.00006198569,0.0001794313,0.00002120808,0.00003307484,0.000682053,0.08187098,0.0000876256],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9711436,0.02378549,0.00001448746,0.002634809,0.000555138,0.0001368483,3.861072e-7,0.000007956599,0.001721262],"genre_scores_gemma":[0.9970699,0.0008811075,0.0002459254,0.0005255445,0.0009053759,0.000001249522,0.000003770881,0.00001053301,0.0003566234],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07835069,"threshold_uncertainty_score":0.3069437,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2318605753","doi":"10.1056/nejm200103153441101","title":"Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2","year":2001,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11512,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Trastuzumab; Epirubicin; Anthracycline; Internal medicine; Breast cancer; Oncology; Cyclophosphamide; Chemotherapy; Doxorubicin; Metastatic breast cancer; Paclitaxel; Cancer; Gastroenterology","retraction":null,"screen_n_in":null,"score":{"opus":0.1035786067360863,"gpt":0.4099576805019227,"spread":0.3063790737658363,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001053889,0.0002645304,0.001101472,0.0003355203,0.00005064461,0.00001955662,0.0002334631,0.00008223623,0.001127677],"category_scores_gemma":[0.0004385646,0.0001702184,0.0001978421,0.000335796,0.0002238442,0.0002181572,0.00002522861,0.0004715393,0.000001481806],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002297163,"about_ca_system_score_gemma":0.00113033,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001128081,"about_ca_topic_score_gemma":0.0001106768,"domain_scores_codex":[0.9972121,0.000110819,0.000793234,0.0002234915,0.001220991,0.0004394237],"domain_scores_gemma":[0.9971818,0.0007055916,0.0005450124,0.0003018759,0.0007113615,0.000554338],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.02924986,0.0007394481,0.125049,0.001403966,0.002198738,0.001346148,0.003724863,0.0008181735,0.1146831,0.00007175334,0.1094285,0.6112865],"study_design_scores_gemma":[0.2179659,0.006786396,0.07845744,0.01027975,0.001161291,0.009575605,0.001049772,0.002382496,0.01474953,0.0005569457,0.6564719,0.0005630027],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9542866,0.006092162,0.003903586,0.03373329,0.0006772438,0.0007884944,0.00009832004,0.00001978376,0.0004004909],"genre_scores_gemma":[0.9658299,0.02063406,0.003722304,0.002662125,0.005389899,0.00001489475,0.00002637717,0.00008570019,0.001634727],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6107234,"threshold_uncertainty_score":0.9997854,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2136489990","doi":"10.1056/nejmoa0905561","title":"Dabigatran versus Warfarin in Patients with Atrial Fibrillation","year":2009,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":11200,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Cilag; Eisai; Sanofi; GlaxoSmithKline; Servier; Daiichi-Sankyo; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Dabigatran; Medicine; Warfarin; Atrial fibrillation; Stroke (engine); Confidence interval; Anesthesia; Internal medicine; Relative risk; Direct thrombin inhibitor","retraction":null,"screen_n_in":null,"score":{"opus":0.03909239909545998,"gpt":0.3114854478571458,"spread":0.2723930487616859,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000406176,0.0001144307,0.0004136514,0.0002758136,0.00002185274,0.000006459161,0.00004957843,0.00004644628,0.0001155827],"category_scores_gemma":[0.0003246567,0.00006791245,0.00008257417,0.0002505242,0.00002708628,0.0001324275,0.000005168095,0.0001606887,0.000002799363],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005742611,"about_ca_system_score_gemma":0.00007172948,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001892919,"about_ca_topic_score_gemma":0.00001238797,"domain_scores_codex":[0.9987161,0.00003939835,0.0004816206,0.00009152922,0.0005353089,0.0001360166],"domain_scores_gemma":[0.9992231,0.0001362857,0.0002563275,0.0001012545,0.0001234912,0.0001595178],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02246091,0.000005441779,0.6982275,0.000009435101,0.00007671521,0.00004545093,0.0002921404,0.0005006067,0.00006798955,0.0001706039,0.0006498809,0.2774934],"study_design_scores_gemma":[0.1869045,0.005611389,0.7828957,0.0001827683,0.0002221833,0.00001983305,0.00003382509,0.00003445873,0.00001872501,0.0001773425,0.02382976,0.00006948915],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9816736,0.0002850093,0.0001640314,0.01549166,0.0007012004,0.0002144572,3.134715e-7,0.0000108794,0.001458842],"genre_scores_gemma":[0.9890037,0.00007854548,0.0005506675,0.0001313872,0.01000651,1.00988e-8,0.00001241784,0.000007600531,0.0002091795],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2774239,"threshold_uncertainty_score":0.2769389,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2527905628","doi":"10.1056/nejmoa1606774","title":"Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10101,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Internal medicine; Hazard ratio; Oncology; Chemotherapy; Cancer; Gastroenterology; Confidence interval; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.01779133937735275,"gpt":0.3044793150951555,"spread":0.2866879757178028,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005723452,0.0002159758,0.000585783,0.000177865,0.00005823892,0.00000744731,0.000148564,0.0001022163,0.0008154823],"category_scores_gemma":[0.0001079538,0.0001115699,0.0002077982,0.0001455138,0.0001200846,0.00008211123,0.000009250748,0.0001848299,0.000001795194],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002622257,"about_ca_system_score_gemma":0.0005432774,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001695969,"about_ca_topic_score_gemma":0.00005081616,"domain_scores_codex":[0.9985745,0.00003591415,0.0005381521,0.0001760255,0.0003731181,0.0003023132],"domain_scores_gemma":[0.99835,0.0004317825,0.000400198,0.0001812927,0.0003375216,0.0002991781],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1490018,0.0001285703,0.003028722,0.0001408678,0.001028348,0.00009506211,0.001755989,0.000001747863,0.2072444,0.00001950355,0.0667982,0.5707568],"study_design_scores_gemma":[0.7013577,0.01042218,0.01401882,0.003090828,0.001128806,0.0005931967,0.0002414491,0.00005445227,0.04767141,0.00009080141,0.2210359,0.0002944557],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9016119,0.01498764,0.009559727,0.06621945,0.003683118,0.0008231336,0.00002405531,0.00002377513,0.003067151],"genre_scores_gemma":[0.9684026,0.009804999,0.0008626743,0.002779841,0.01206266,0.00001429198,0.000005484453,0.00005838128,0.006009116],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5704623,"threshold_uncertainty_score":0.8928959,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2748400555","doi":"10.1056/nejmoa1707914","title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Inflammasome and immune disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9109,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"National Institute of Neurological Disorders and Stroke","keywords":"Canakinumab; Medicine; Placebo; Myocardial infarction; Hazard ratio; Internal medicine; Confidence interval; Randomized controlled trial; Clinical endpoint; C-reactive protein; Surgery; Gastroenterology; Inflammation; Disease; Pathology; Anakinra","retraction":null,"screen_n_in":null,"score":{"opus":0.01683589248186131,"gpt":0.2681017057267959,"spread":0.2512658132449346,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002986351,0.0001078003,0.000179074,0.00003328044,0.0001417775,0.00001760222,0.0002519776,0.0000361432,0.00002143985],"category_scores_gemma":[0.0001955795,0.00006454015,0.00006098013,0.00001171725,0.0001246612,0.000008519128,0.00001435838,0.00007266302,5.255757e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000005730426,"about_ca_system_score_gemma":0.0002234674,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003849007,"about_ca_topic_score_gemma":0.00006738611,"domain_scores_codex":[0.9994026,0.00002113371,0.0001976905,0.00009471545,0.000139824,0.000144022],"domain_scores_gemma":[0.9990832,0.00001273461,0.0003144704,0.0002955302,0.0001489591,0.000145152],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01858122,0.0001452844,0.08391861,0.00008395752,0.0007846315,0.0001457396,0.0008856225,0.0001334965,0.366823,0.0003026088,0.0247571,0.5034388],"study_design_scores_gemma":[0.1145646,0.005776859,0.1209334,0.0003302728,0.0001457265,0.000147184,0.0001906524,0.00002723747,0.02590198,0.000488817,0.7311745,0.0003187736],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932047,0.002300543,0.0008967363,0.002740923,0.0003060211,0.0001376475,0.000002259016,0.000001858882,0.000409379],"genre_scores_gemma":[0.9956403,0.001068992,0.0001484896,0.0002866451,0.002196807,0.000002368472,0.000008594316,0.00001737806,0.0006303759],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7064174,"threshold_uncertainty_score":0.2631871,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2162508946","doi":"10.1056/nejmoa1107039","title":"Apixaban versus Warfarin in Patients with Atrial Fibrillation","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":8914,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"","keywords":"Apixaban; Atrial fibrillation; Warfarin; Cardiology; Medicine; Internal medicine; Rivaroxaban","retraction":null,"screen_n_in":null,"score":{"opus":0.07181510108788432,"gpt":0.3023844160813428,"spread":0.2305693149934585,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004285421,0.0001109739,0.0003868481,0.0002947134,0.00001951429,0.00000365226,0.0000525059,0.00004576597,0.0003860609],"category_scores_gemma":[0.0003355849,0.00006538998,0.00007665267,0.0002166127,0.00003930254,0.0001315463,0.00001262448,0.0001459106,0.000005760553],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004990207,"about_ca_system_score_gemma":0.00006898251,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008226634,"about_ca_topic_score_gemma":0.00002931254,"domain_scores_codex":[0.9988063,0.00004291721,0.0004698199,0.00008960909,0.0004599509,0.000131389],"domain_scores_gemma":[0.9991833,0.0001214312,0.0002961642,0.0001055749,0.0001387403,0.0001548109],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02185752,0.000004536325,0.9004599,0.00001202083,0.0001109944,0.00003294211,0.0007262875,0.00003994523,0.000008740779,0.0001459611,0.0004182226,0.07618293],"study_design_scores_gemma":[0.1612622,0.003833588,0.8165382,0.0001526457,0.0002470757,0.00001463321,0.00007086552,0.00001817049,0.00001581914,0.0001212206,0.0176579,0.00006761297],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930273,0.000210587,0.0002018575,0.001924865,0.001025851,0.0002156339,3.420569e-7,0.00001022844,0.003383298],"genre_scores_gemma":[0.9915971,0.00006082128,0.0009334282,0.0000504759,0.007045691,2.497373e-8,0.000008468045,0.00001187467,0.0002921009],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1394047,"threshold_uncertainty_score":0.4227096,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2166662937","doi":"10.1056/nejmoa1504030","title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8144,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hotel Dieu Hospital","funders":"National Cancer Institute","keywords":"Nivolumab; Ipilimumab; Medicine; Melanoma; Oncology; Metastatic melanoma; Internal medicine; Dermatology; Immunotherapy; Cancer research; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.03693018645658255,"gpt":0.2979048351264862,"spread":0.2609746486699037,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008945439,0.0001523628,0.0005796016,0.0002939526,0.00001890946,0.00000817655,0.00007915643,0.00007842531,0.0002698424],"category_scores_gemma":[0.0002019967,0.00008549287,0.00004315851,0.00029034,0.0001219128,0.00008279349,0.000008885978,0.0002491896,0.000001576891],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001222036,"about_ca_system_score_gemma":0.0004009325,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006296596,"about_ca_topic_score_gemma":0.000233004,"domain_scores_codex":[0.9987099,0.00008286629,0.0005562599,0.000117404,0.0003575801,0.0001760483],"domain_scores_gemma":[0.9990255,0.0001285735,0.0002176983,0.0001360754,0.0001464262,0.0003457482],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2128833,0.0002811393,0.07946607,0.0000578887,0.0004624344,0.001839202,0.006859006,0.000006238468,0.01006321,0.00004113045,0.0270822,0.6609582],"study_design_scores_gemma":[0.7747108,0.02703359,0.07620902,0.001366533,0.000237224,0.005967267,0.001577728,0.0001901703,0.001202161,0.0006771518,0.1105927,0.0002356755],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9774784,0.006373357,0.00007560381,0.01449906,0.0004237994,0.0001765827,9.467872e-7,0.00001228496,0.0009599125],"genre_scores_gemma":[0.9934939,0.002271473,0.0003248501,0.001154035,0.001181677,0.0000010074,0.000003754159,0.00001929427,0.001550009],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6607225,"threshold_uncertainty_score":0.3486298,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2128542677","doi":"10.1056/nejmoa1103782","title":"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7688,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Vemurafenib; Medicine; Dacarbazine; Interim analysis; Internal medicine; Adverse effect; Melanoma; Oncology; Rash; Dabrafenib; Progression-free survival; Nausea; Clinical trial; Cancer research; Metastatic melanoma; Chemotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.0159994996001733,"gpt":0.22066546399615,"spread":0.2046659643959767,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003928004,0.0001248027,0.0002336213,0.0000854891,0.00001877638,0.000003868903,0.0001179444,0.00006452744,0.00004816574],"category_scores_gemma":[0.00005677231,0.00007046247,0.00002316869,0.00008589045,0.000064758,0.000007591206,0.00001177616,0.0001458482,7.827972e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000009118105,"about_ca_system_score_gemma":0.0001512673,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001793062,"about_ca_topic_score_gemma":0.0007822742,"domain_scores_codex":[0.9992082,0.00006205835,0.0002691626,0.0001274367,0.0001788419,0.0001542667],"domain_scores_gemma":[0.9993707,0.00001888711,0.0002131266,0.0001332506,0.0001172269,0.000146794],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01845354,0.0003154675,0.1182243,0.00008120484,0.0004332068,0.002334859,0.005860635,0.00005098737,0.7096181,0.0004183417,0.001395247,0.1428142],"study_design_scores_gemma":[0.2656659,0.08820555,0.2284072,0.0009640936,0.0004694975,0.01354204,0.00273776,0.0001264636,0.3452905,0.0007269816,0.05277717,0.001086796],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930816,0.0003796256,0.002767026,0.0002959798,0.0002129697,0.00008507541,0.000001178631,0.000002975023,0.003173555],"genre_scores_gemma":[0.9969872,0.00006286081,0.001361816,0.0001094582,0.001195598,0.000001278251,0.00001310823,0.00001478134,0.0002538865],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3643276,"threshold_uncertainty_score":0.2873376,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1526927233","doi":"10.1056/nejmoa0802987","title":"Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes","year":2008,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7418,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"National Health and Medical Research Council; Medical Research Council; GW Pharmaceuticals; Gilead Sciences; Novo Nordisk; Daiichi Sankyo Europe; Sanofi; GlaxoSmithKline; Servier; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Hazard ratio; Glycated hemoglobin; Internal medicine; Type 2 diabetes; Retinopathy; Nephropathy; Diabetes mellitus; Diabetic retinopathy; Albuminuria; Incidence (geometry); Stroke (engine); Confidence interval; Endocrinology; Renal function","retraction":null,"screen_n_in":null,"score":{"opus":0.006932252723265506,"gpt":0.2100692941222603,"spread":0.2031370413989948,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002137836,0.0001387542,0.0006128887,0.0002153193,0.00002172288,0.000003091347,0.00004369381,0.00003022237,0.00003605599],"category_scores_gemma":[0.0003156579,0.00007197069,0.00003688799,0.0001202205,0.00009080408,0.00007241795,0.00001182951,0.0001540096,0.000001597038],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000218093,"about_ca_system_score_gemma":0.00004299034,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001712601,"about_ca_topic_score_gemma":0.000006999806,"domain_scores_codex":[0.9990453,0.00003292915,0.0002967105,0.00009957184,0.0003573026,0.0001682376],"domain_scores_gemma":[0.9991133,0.0001068737,0.000147999,0.0001090602,0.0003247737,0.0001980584],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0005291179,0.0002302941,0.9854238,0.00002195335,0.0007840167,0.0002281058,0.000442978,0.000002418411,0.0000778221,0.000009196016,0.0008098155,0.01144047],"study_design_scores_gemma":[0.15432,0.006494056,0.8352917,0.0002972063,0.0008729087,0.00002446698,0.00006614866,0.000005571175,0.00004658077,0.00003078963,0.002487291,0.00006325437],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949793,0.002115577,0.00001000187,0.002304735,0.0001622985,0.0002343528,6.03144e-7,0.00000632454,0.0001868594],"genre_scores_gemma":[0.9973421,0.0006016428,0.0001885157,0.001396152,0.0002772215,9.983115e-7,0.000005643018,0.00001204485,0.0001756503],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1537909,"threshold_uncertainty_score":0.293488,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2425644022","doi":"10.1056/nejmoa1603827","title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7350,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"National Center for Advancing Translational Sciences; Relypsa; National Institutes of Health; ResMed; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Orexigen Therapeutics; Massachusetts Medical Society; Novo Nordisk; Intarcia Therapeutics; Sanofi; Esperion Therapeutics; GlaxoSmithKline; Amgen; Pfizer; Celgene","keywords":"Liraglutide; Type 2 diabetes; Medicine; Internal medicine; Diabetes mellitus; Cardiology; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.01427990771717185,"gpt":0.2462845114180889,"spread":0.232004603700917,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006895917,0.0001099473,0.0006025514,0.0002244424,0.00001094258,0.000003491054,0.00004875091,0.00003048071,0.0001103861],"category_scores_gemma":[0.0004070194,0.00004917575,0.00008082971,0.0001043231,0.00005987625,0.00007303841,0.0000201628,0.00008361498,0.000004969131],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003307353,"about_ca_system_score_gemma":0.000036876,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001921694,"about_ca_topic_score_gemma":0.000007994039,"domain_scores_codex":[0.9990858,0.00003804049,0.0002968724,0.0000975857,0.0003162799,0.0001654652],"domain_scores_gemma":[0.9993594,0.0001552572,0.00007796252,0.0001528041,0.00006742621,0.0001871889],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001215981,0.00004329258,0.5047436,0.0000251558,0.0006776187,0.0002132488,0.0001284607,9.502967e-7,0.0007582256,0.00007682592,0.002927558,0.4902835],"study_design_scores_gemma":[0.1121751,0.003528185,0.6486555,0.001412583,0.00126523,0.0001229709,0.00009892961,0.000004624247,0.000592148,0.001151036,0.2308549,0.0001387612],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9723498,0.0117545,0.00004796821,0.01375819,0.0003951623,0.000116913,3.4388e-7,0.000007936817,0.001569171],"genre_scores_gemma":[0.9939917,0.003131516,0.0002589196,0.0004347122,0.0007950097,7.333074e-7,6.708083e-7,0.00001033246,0.00137639],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4901447,"threshold_uncertainty_score":0.2005329,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2105100844","doi":"10.1056/nejmoa043331","title":"<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma","year":2005,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":7252,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"","keywords":"Temozolomide; Medicine; O-6-methylguanine-DNA methyltransferase; Methyltransferase; Hazard ratio; Oncology; Methylation; Confidence interval; DNA methylation; Internal medicine; Radiation therapy; Cancer research; DNA methyltransferase; Biology; Gene; Genetics; Gene expression","retraction":null,"screen_n_in":null,"score":{"opus":0.01129808041401682,"gpt":0.2508328307641014,"spread":0.2395347503500846,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003629724,0.0001627595,0.0005815524,0.0002770521,0.00002711206,0.000007907982,0.00006310392,0.00006663756,0.0001746514],"category_scores_gemma":[0.000147857,0.0001032598,0.00005414353,0.000154281,0.00005086987,0.00009657749,0.00001939115,0.0002551492,0.0000060635],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000969676,"about_ca_system_score_gemma":0.0000607916,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004585685,"about_ca_topic_score_gemma":0.0006683539,"domain_scores_codex":[0.9987007,0.00002262507,0.0005718629,0.0001516947,0.0003555775,0.0001975376],"domain_scores_gemma":[0.9989272,0.0002620617,0.0002171584,0.0001372406,0.00008157618,0.0003747678],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.002134135,0.0004095883,0.224573,0.00002585983,0.000263037,0.003140171,0.002740237,0.0001918,0.09256383,0.00009664192,0.005625017,0.6682367],"study_design_scores_gemma":[0.3136562,0.008617876,0.4966955,0.00353221,0.001152926,0.01104799,0.0008048512,0.0005506657,0.1101555,0.002573367,0.0508127,0.0004001676],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9698646,0.01209335,0.00002912592,0.01736517,0.0002053643,0.0001020609,0.000002889782,0.000008102153,0.0003292991],"genre_scores_gemma":[0.9916166,0.001739837,0.00151098,0.00114271,0.003896442,0.000001285101,0.00000294284,0.00001560386,0.00007360512],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6678365,"threshold_uncertainty_score":0.4210814,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3025022288","doi":"10.1056/nejmoa1915745","title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":7245,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Roche (Canada)","funders":"Bayer Yakuhin; Eli Lilly Japan; Chugai Pharmaceutical; Novartis Pharma; Genentech; Sirtex Medical; Ipsen; Dainippon Sumitomo Pharma; Yakult Honsha; Gilead Sciences; Servier; Advanced Accelerator Applications; Teijin Pharma; Otsuka Pharmaceutical; Eisai; BeiGene; Cisco Systems; F. Hoffmann-La Roche; Ipsen Biopharmaceuticals; Taiho Pharmaceutical; EA Pharma Co., Ltd.; Baxalta; Bayer HealthCare; Exelixis; Sanofi; Amgen; Pfizer; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atezolizumab; Bevacizumab; Hepatocellular carcinoma; Medicine; Oncology; Internal medicine; Carcinoma; Cancer; Chemotherapy; Immunotherapy; Nivolumab","retraction":null,"screen_n_in":null,"score":{"opus":0.0791161146425367,"gpt":0.264622043496366,"spread":0.1855059288538293,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005996425,0.0002786477,0.001036088,0.0003204893,0.00004234904,0.00001289299,0.0001896134,0.0001258108,0.0007648121],"category_scores_gemma":[0.0004743882,0.0001910451,0.0001787575,0.0005730366,0.00008371042,0.0001368521,0.00003827989,0.0006188889,0.00003095136],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002035909,"about_ca_system_score_gemma":0.0006220617,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004297089,"about_ca_topic_score_gemma":0.00002365507,"domain_scores_codex":[0.9976178,0.0001465801,0.0008833923,0.000247738,0.0007151703,0.0003893134],"domain_scores_gemma":[0.9982477,0.0001548321,0.0002881589,0.0002071134,0.0001953767,0.0009068429],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.004748455,0.0001016047,0.9350603,0.0001659132,0.000151329,0.01250873,0.004112429,0.00001226357,0.005177457,0.00008930539,0.006024811,0.0318474],"study_design_scores_gemma":[0.6097218,0.02722044,0.09143737,0.002191978,0.002122857,0.01139712,0.001701429,0.02750975,0.02498042,0.0009206189,0.1998629,0.0009333241],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9600632,0.008668344,0.0003343683,0.02782355,0.0002700627,0.0003561795,0.00000221877,0.00002255965,0.002459535],"genre_scores_gemma":[0.9940333,0.0004207636,0.0004288817,0.001162433,0.00356936,0.000003195834,0.00001887682,0.00003774296,0.0003253839],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8436229,"threshold_uncertainty_score":0.8374156,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2149609916","doi":"10.1056/nejmoa1008232","title":"Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery","year":2010,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cardiac Valve Diseases and Treatments","field":"Medicine","cited_by":7161,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Stenosis; Aortic valve replacement; Cardiology; Internal medicine; Aortic valve stenosis; Aortic valve; Surgery","retraction":null,"screen_n_in":null,"score":{"opus":0.01625634126405529,"gpt":0.3120765444328715,"spread":0.2958202031688162,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004038543,0.0001581582,0.0006197703,0.0002886833,0.000031947,0.000008253437,0.00004906587,0.00007082409,0.00009989984],"category_scores_gemma":[0.0003461773,0.0001043173,0.0007997623,0.000134594,0.00004043547,0.00009383407,0.000004496284,0.000229823,0.000001908099],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005977042,"about_ca_system_score_gemma":0.0002176757,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001832048,"about_ca_topic_score_gemma":0.00003842144,"domain_scores_codex":[0.9985567,0.0000361955,0.0006259886,0.0001355719,0.0004108838,0.0002346007],"domain_scores_gemma":[0.9986095,0.0003831834,0.0002610421,0.0001393617,0.0002475462,0.0003593076],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00193915,0.0002723847,0.8937595,0.00007352239,0.0005992358,0.00001188954,0.0006972711,0.00000262465,0.000236978,0.00001278779,0.001558128,0.1008365],"study_design_scores_gemma":[0.04517009,0.001113218,0.950089,0.0003450192,0.001582894,0.00004586007,0.00007639747,0.00001187884,0.00009682313,0.0002063577,0.001172335,0.00009015753],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959624,0.0002180775,0.0001446444,0.002136272,0.001088543,0.0003248843,0.0000224139,0.000006079756,0.00009665419],"genre_scores_gemma":[0.9976979,0.0001598309,0.0001002554,0.0004910139,0.00138655,0.00000665185,0.00006588401,0.00002319204,0.00006874141],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1007464,"threshold_uncertainty_score":0.4253934,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2974260792","doi":"10.1056/nejmoa1911303","title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6873,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Montreal Heart Institute; Libin Cardiovascular Institute of Alberta; St. Michael's Hospital; University of Calgary","funders":"AstraZeneca","keywords":"Dapagliflozin; Ejection fraction; Heart failure; Cardiology; Internal medicine; Fraction (chemistry); Medicine; Chemistry; Diabetes mellitus; Endocrinology; Chromatography","retraction":null,"screen_n_in":null,"score":{"opus":0.005921450203652242,"gpt":0.2270162747503756,"spread":0.2210948245467234,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002494582,0.00008898212,0.0003041449,0.0002320687,0.00001182214,0.000005269987,0.00002054959,0.00003232395,0.0001200607],"category_scores_gemma":[0.00004253081,0.00005141042,0.00001796147,0.000125299,0.00001926604,0.0001302819,0.000006662105,0.0001687583,0.000004859764],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005859444,"about_ca_system_score_gemma":0.00002953803,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003033779,"about_ca_topic_score_gemma":0.0000138564,"domain_scores_codex":[0.9992715,0.00002615849,0.0002187223,0.00009126908,0.0002887885,0.000103558],"domain_scores_gemma":[0.9995565,0.00003737184,0.0001281585,0.00008190188,0.00007872829,0.0001173725],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001311455,0.000122312,0.970643,0.00003564942,0.00008024683,0.00001317881,0.0001124175,0.000006707753,0.0008856452,0.00001428924,0.005537477,0.02123763],"study_design_scores_gemma":[0.07997376,0.005948907,0.8715541,0.0006141206,0.0001892712,0.00003524228,0.0001881248,0.00001255972,0.0001410629,0.00005196125,0.04123404,0.00005681452],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926656,0.0001520367,0.00002487632,0.005794375,0.00024321,0.000238204,1.768655e-7,0.00000591843,0.0008755872],"genre_scores_gemma":[0.9981419,0.00003940918,0.0004855732,0.000300396,0.0005241556,6.780684e-7,0.000007283367,0.000008825229,0.0004917534],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09908886,"threshold_uncertainty_score":0.2096456,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2113698123","doi":"10.1056/nejmoa1409077","title":"Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":6845,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"","keywords":"Enalapril; Neprilysin; Heart failure; Internal medicine; Cardiology; Renin–angiotensin system; Medicine; Angiotensin-converting enzyme; Chemistry; Blood pressure; Enzyme; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.01765870999394022,"gpt":0.2696066453023074,"spread":0.2519479353083672,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001064896,0.0001536205,0.0005511258,0.0003993491,0.00002680513,0.000007792351,0.00004264121,0.00007222783,0.0002465353],"category_scores_gemma":[0.0004449364,0.00009981078,0.00009591485,0.0002589909,0.00005708387,0.00009819864,0.00001668819,0.0003028091,0.00002565737],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008874315,"about_ca_system_score_gemma":0.00008777808,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001008897,"about_ca_topic_score_gemma":0.0001653207,"domain_scores_codex":[0.9985722,0.0001060764,0.000491159,0.0001360002,0.0004740411,0.0002205046],"domain_scores_gemma":[0.999066,0.0001782402,0.0001489097,0.0001735439,0.0001327171,0.0003006205],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.006598588,0.0004214205,0.03169036,0.0001010692,0.0003760128,0.001102416,0.001841171,0.00008452413,0.02172492,0.001295219,0.7289006,0.2058637],"study_design_scores_gemma":[0.1156077,0.003795854,0.0196794,0.0007867516,0.0003051328,0.0006301139,0.0001662632,0.00007490673,0.0009523653,0.0003883771,0.8575032,0.000109903],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.688741,0.0005325144,0.001142467,0.3064896,0.0008454478,0.0002476978,3.454615e-7,0.00002532242,0.001975563],"genre_scores_gemma":[0.9871035,0.00008487957,0.006579578,0.001423252,0.004348038,8.846287e-7,0.000009331205,0.00001555809,0.0004349768],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3050663,"threshold_uncertainty_score":0.4070165,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2137983259","doi":"10.1056/nejmoa0807646","title":"Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein","year":2008,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":6637,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Rosuvastatin; Medicine; Hazard ratio; C-reactive protein; Rosuvastatin Calcium; Internal medicine; Myocardial infarction; Confidence interval; Statin; Placebo; Unstable angina; Cardiology; Endocrinology; Gastroenterology; Inflammation; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.01090383226407039,"gpt":0.2479458575564496,"spread":0.2370420252923792,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001756203,0.0001710929,0.0007477062,0.0002729115,0.00004166827,0.000002108928,0.00006872099,0.00005268038,0.00005079882],"category_scores_gemma":[0.0002630532,0.000100072,0.00004872911,0.0003269826,0.00005168169,0.00008270062,0.00001902286,0.0003825891,0.000001777639],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001928868,"about_ca_system_score_gemma":0.000411566,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005132561,"about_ca_topic_score_gemma":0.00003231121,"domain_scores_codex":[0.9979905,0.0001647883,0.000487734,0.0001796538,0.0008770992,0.0003001876],"domain_scores_gemma":[0.9987114,0.00003782515,0.0001904598,0.0002103742,0.0001905177,0.0006594144],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.03667253,0.002287135,0.1261268,0.001102027,0.004447022,0.01055021,0.1049475,0.0003257336,0.09491721,0.00008890015,0.003440298,0.6150947],"study_design_scores_gemma":[0.2107551,0.02498557,0.7076876,0.004896411,0.0003776652,0.01325491,0.003604054,0.00003780988,0.006330918,0.0004607502,0.02716831,0.0004409091],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940754,0.0009558081,0.0006255909,0.003122912,0.00004225706,0.0008851672,7.305375e-7,0.000007860359,0.0002842792],"genre_scores_gemma":[0.9968796,0.0002673066,0.001178022,0.0003397119,0.0009526976,0.00002134335,0.000001915137,0.00002280987,0.0003365842],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6146538,"threshold_uncertainty_score":0.4080816,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2796582438","doi":"10.1056/nejmoa1801005","title":"Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6613,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Merck","keywords":"Pembrolizumab; Chemotherapy; Lung cancer; Medicine; Oncology; Internal medicine; Cancer; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.01975310630683914,"gpt":0.3120918999598457,"spread":0.2923387936530065,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008693945,0.0001944449,0.0006771708,0.0003336319,0.00003635243,0.000008433301,0.0001533555,0.00006101101,0.001746983],"category_scores_gemma":[0.00006349445,0.000122538,0.0001081531,0.0003689446,0.0001641192,0.00007084013,0.00001055107,0.000355265,0.000003346308],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002584842,"about_ca_system_score_gemma":0.0008082131,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001045888,"about_ca_topic_score_gemma":0.0004100194,"domain_scores_codex":[0.9983981,0.00006111371,0.0006819741,0.0001520248,0.0004266365,0.0002801472],"domain_scores_gemma":[0.998899,0.000102388,0.0003532336,0.0001868767,0.0002122008,0.0002462592],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.06940269,0.0004472002,0.04427366,0.0006000112,0.001301999,0.001262157,0.0210356,0.00003802907,0.1460354,0.00002130228,0.09029123,0.6252908],"study_design_scores_gemma":[0.699496,0.009623757,0.06971998,0.004369799,0.001102233,0.003315863,0.001066102,0.001576351,0.01782194,0.0001957315,0.1912626,0.000449596],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9674404,0.01283055,0.0009542705,0.01450415,0.001125049,0.0003094895,0.000001687325,0.00001000398,0.002824413],"genre_scores_gemma":[0.9826633,0.004636517,0.0007557616,0.003805279,0.005948776,0.000003703294,0.000002310034,0.00003242356,0.002151951],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6300933,"threshold_uncertainty_score":0.9991655,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2519510391","doi":"10.1056/nejmoa1607141","title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","year":2016,"lang":"en","type":"letter","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6603,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Manitoba; University of Toronto; St. Michael's Hospital","funders":"Servier; Novo Nordisk Fonden; Medicines Company; Novo Nordisk; Intarcia Therapeutics; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Mylan; MannKind Corporation; GlaxoSmithKline","keywords":"Semaglutide; Type 2 diabetes; Medicine; Diabetes mellitus; Internal medicine; Cardiology; Endocrinology; Liraglutide","retraction":null,"screen_n_in":null,"score":{"opus":0.008063027747281284,"gpt":0.2113504001113577,"spread":0.2032873723640764,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004970062,0.0003079358,0.001469393,0.0004660959,0.0000165704,0.000008448258,0.00009727086,0.0001623549,0.0001069065],"category_scores_gemma":[0.0002110521,0.0001402609,0.0001294851,0.0001215291,0.00009953059,0.00005734191,0.00003074032,0.0006238,0.000004735641],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007349998,"about_ca_system_score_gemma":0.00008107373,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001915334,"about_ca_topic_score_gemma":0.000003860372,"domain_scores_codex":[0.9980605,0.00007389581,0.0004601929,0.0002081704,0.0008770467,0.0003201546],"domain_scores_gemma":[0.9988598,0.0002201316,0.0002539412,0.0003052492,0.0001957408,0.0001651688],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001931521,0.00003451279,0.5619485,0.0001525294,0.002470959,0.0007461012,0.00006443955,4.843528e-7,0.000001803236,0.000001167206,0.3328839,0.1015025],"study_design_scores_gemma":[0.0683291,0.003321993,0.1937973,0.002021923,0.002172289,0.0000196036,0.000007115811,2.690511e-7,0.000004214843,0.00005690969,0.7301288,0.0001405649],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.4830832,0.008366426,0.000009889119,0.5055591,0.0009909298,0.0005933032,0.000005591276,0.00001601713,0.001375597],"genre_scores_gemma":[0.3292003,0.004239501,0.001291738,0.600768,0.04340801,0.00001448897,0.0002516346,0.0003180106,0.02050837],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.3972449,"threshold_uncertainty_score":0.5719674,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2110664940","doi":"10.1056/nejmoa0912217","title":"Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer","year":2010,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":6532,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Institute of Dental and Craniofacial Research; National Cancer Institute","keywords":"Medicine; Hazard ratio; Radiation therapy; Internal medicine; Oncology; Dose fractionation; Cancer; Proportional hazards model; Stage (stratigraphy); Survival analysis; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.01735811462314137,"gpt":0.303350101630033,"spread":0.2859919870068916,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003141035,0.0001154959,0.0006648037,0.00009842831,0.00004386135,0.000002049813,0.00005245127,0.00004125846,0.0002743239],"category_scores_gemma":[0.00009731669,0.00006041051,0.00002819534,0.00009038514,0.0001987316,0.0000509813,0.00001483026,0.0003573761,2.58634e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001364479,"about_ca_system_score_gemma":0.0001272992,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003476649,"about_ca_topic_score_gemma":0.0004497902,"domain_scores_codex":[0.9989594,0.00002308894,0.0003569167,0.00008888733,0.0004382194,0.0001334583],"domain_scores_gemma":[0.9990161,0.0000627628,0.0002441542,0.00009661747,0.0003220577,0.0002583134],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001674409,0.0001149222,0.8825037,0.0001067939,0.0002206422,0.00007968579,0.001275734,3.787317e-7,0.01927634,0.00008409114,0.003938185,0.09072512],"study_design_scores_gemma":[0.06173961,0.004426713,0.915023,0.0004828567,0.0002875496,0.0000716295,0.0001008919,8.706986e-7,0.0006315276,0.00005381622,0.01711092,0.00007055854],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936348,0.001501442,0.000007170954,0.002815469,0.0005957594,0.00008714713,0.000004427302,0.000003692308,0.001350114],"genre_scores_gemma":[0.9965864,0.0004795619,0.0001393249,0.0002536929,0.002299174,7.15071e-7,0.000001836152,0.00001234893,0.0002269677],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09065457,"threshold_uncertainty_score":0.3003654,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1553345686","doi":"10.1056/nejmoa010746","title":"Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation","year":2001,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":6486,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Population Health Research Institute; Hamilton General Hospital","funders":"","keywords":"Medicine; Clopidogrel; Aspirin; Placebo; Internal medicine; Myocardial infarction; Relative risk; Stroke (engine); Acute coronary syndrome; Confidence interval; Cardiology; Anesthesia; Surgery","retraction":null,"screen_n_in":null,"score":{"opus":0.006613261563669518,"gpt":0.240237507539794,"spread":0.2336242459761245,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003902136,0.0001292518,0.0005664701,0.0003607374,0.00001162621,0.000002118321,0.00005949404,0.00004790042,0.0000726811],"category_scores_gemma":[0.00008563422,0.0000822347,0.00006682055,0.0003092091,0.00003836117,0.00009782642,0.000008409404,0.00018288,0.000001246559],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007788309,"about_ca_system_score_gemma":0.000101141,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003188455,"about_ca_topic_score_gemma":0.00001893483,"domain_scores_codex":[0.9985977,0.00009296556,0.0004406784,0.0001127473,0.0006064195,0.0001494466],"domain_scores_gemma":[0.9992956,0.00007907529,0.0001932926,0.000109085,0.0001394665,0.0001834663],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01098279,0.0003804167,0.7613707,0.0001013422,0.0003967218,0.001296912,0.0004023118,0.0001064315,0.0005192279,0.000006450822,0.0003305745,0.2241061],"study_design_scores_gemma":[0.08904196,0.006323935,0.898827,0.002579798,0.0003321047,0.0005272778,0.00005684027,0.000007078094,0.0002088244,0.00003957293,0.001979461,0.00007617113],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967215,0.001006285,0.001052203,0.0006167091,0.0001290313,0.0004240143,0.000002837746,0.000004864084,0.00004254682],"genre_scores_gemma":[0.9981852,0.0007709552,0.0003078289,0.0003271384,0.0003152891,0.000003957474,0.00003049081,0.0000135676,0.00004560471],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2240299,"threshold_uncertainty_score":0.3353434,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2027545702","doi":"10.1056/nejmoa020047","title":"Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection","year":2002,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":6397,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Nutrasource","funders":"National Center for Research Resources","keywords":"Ribavirin; Medicine; Peginterferon alfa-2a; Internal medicine; Gastroenterology; Interferon alfa; Alpha interferon; Hepatitis C; Hepatitis C virus; Placebo; Interferon; Immunology; Virus; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.06331394442343537,"gpt":0.3399126845956345,"spread":0.2765987401721992,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009856916,0.0002019165,0.0006796132,0.0004419509,0.00008188924,0.00001725011,0.0001343767,0.0001189173,0.002661267],"category_scores_gemma":[0.001239712,0.0001439004,0.000157022,0.0002390542,0.0001312474,0.0001765445,0.00002639104,0.0006260991,0.00006413593],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006160768,"about_ca_system_score_gemma":0.0002663193,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003128622,"about_ca_topic_score_gemma":0.00320464,"domain_scores_codex":[0.9978276,0.0001152326,0.0007182217,0.0001876707,0.0007548649,0.0003964072],"domain_scores_gemma":[0.9982082,0.0002980886,0.0002875912,0.0002384304,0.0004143249,0.0005534063],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0011271,0.0001326079,0.03433419,0.000226115,0.0002461229,0.0004305503,0.001084462,0.00007144854,0.01054463,0.00006568684,0.1402442,0.8114929],"study_design_scores_gemma":[0.09021267,0.01640195,0.01985146,0.001383066,0.0003453475,0.002107853,0.00001669496,0.005820223,0.002706266,0.0002725607,0.8606668,0.0002151739],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9336953,0.009384773,0.01916237,0.02606008,0.002375561,0.001003467,0.00001651172,0.00006315733,0.008238847],"genre_scores_gemma":[0.9659842,0.01806078,0.0004249587,0.0005074859,0.01132689,0.000009540294,0.00001219013,0.00004457185,0.003629381],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8112777,"threshold_uncertainty_score":0.9982504,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2165258820","doi":"10.1056/nejmoa1103510","title":"Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cardiac Valve Diseases and Treatments","field":"Medicine","cited_by":6325,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Valve replacement; Stenosis; Aortic valve replacement; Surgery; Confidence interval; Aortic valve stenosis; Clinical endpoint; Stroke (engine); Randomized controlled trial; Cardiology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.02229107402632935,"gpt":0.3064864526106799,"spread":0.2841953785843506,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004180835,0.0001650435,0.0005514956,0.0001897763,0.00002242338,0.00000306051,0.00006585823,0.0000569985,0.0007553383],"category_scores_gemma":[0.0001665669,0.0001010409,0.0006716614,0.0001296601,0.00005344491,0.00006205074,0.00001093856,0.0002630607,0.00001050221],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009578524,"about_ca_system_score_gemma":0.00008974854,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004824974,"about_ca_topic_score_gemma":0.00001341532,"domain_scores_codex":[0.998409,0.00009418796,0.0005880599,0.0001508168,0.0005375684,0.0002203671],"domain_scores_gemma":[0.9988552,0.0001197149,0.0002492726,0.0001886316,0.0001397508,0.0004473748],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01833904,0.0006564471,0.9045944,0.0000168826,0.001095855,0.0001498571,0.001266481,0.000001552902,0.000003449587,0.00003248781,0.0007237121,0.07311988],"study_design_scores_gemma":[0.2129425,0.006977346,0.7748081,0.0002327116,0.001985706,0.00006682947,0.0001058255,0.000002995151,0.00002938723,0.0001533396,0.002616236,0.00007908077],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954922,0.001019249,0.00002324746,0.0003284325,0.00105616,0.0001918781,0.000007537326,0.000007136111,0.001874133],"genre_scores_gemma":[0.9978003,0.0007236272,0.0001600535,0.00008510928,0.001103051,0.000002205479,0.00001739937,0.00001706991,0.00009117166],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1946034,"threshold_uncertainty_score":0.8270425,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2900413769","doi":"10.1056/nejmoa1812389","title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6310,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"AstraZeneca","keywords":"Dapagliflozin; Mace; Medicine; Hazard ratio; Myocardial infarction; Internal medicine; Type 2 diabetes; Diabetes mellitus; Stroke (engine); Placebo; Cardiology; Heart failure; Confidence interval; Endocrinology; Percutaneous coronary intervention","retraction":null,"screen_n_in":null,"score":{"opus":0.01643180572280189,"gpt":0.2611640940270873,"spread":0.2447322883042854,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007641376,0.0001139908,0.0006157435,0.0002475762,0.00001776244,0.000005743751,0.00005423137,0.00003391769,0.0001392004],"category_scores_gemma":[0.00029778,0.00006604449,0.0000702874,0.0001594415,0.0001059035,0.00006330517,0.00002266736,0.0001235836,0.000006925768],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002473628,"about_ca_system_score_gemma":0.00003903855,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003225719,"about_ca_topic_score_gemma":0.00001770197,"domain_scores_codex":[0.9990562,0.00003903163,0.0003004497,0.000103256,0.0003338718,0.0001671607],"domain_scores_gemma":[0.999385,0.00007805706,0.00007718846,0.0001636081,0.0001111414,0.0001849816],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002414254,0.00008917798,0.5973462,0.00004771899,0.001255324,0.0002411742,0.000661807,0.000002047489,0.0004451796,0.0001033809,0.009550666,0.3900159],"study_design_scores_gemma":[0.09675416,0.008233279,0.5423305,0.0008357381,0.001829848,0.0001406458,0.0002863445,0.00004897358,0.0006248947,0.0009068912,0.34784,0.0001686708],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.980701,0.009559094,0.00002533358,0.005495709,0.000611858,0.0001272085,2.356588e-7,0.000008018539,0.003471559],"genre_scores_gemma":[0.9949927,0.001007511,0.0004745529,0.0006706534,0.001981375,5.963311e-7,0.00000174989,0.00001095106,0.0008598602],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3898472,"threshold_uncertainty_score":0.2693217,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1982488143","doi":"10.1056/nejmoa1501824","title":"Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6228,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Oncology; Internal medicine; PD-L1; Cancer; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.03835118192736064,"gpt":0.3276515059079407,"spread":0.28930032398058,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004998445,0.0001222081,0.0004452253,0.00008966957,0.0000291927,0.000003384394,0.00009547953,0.00004460709,0.0001251094],"category_scores_gemma":[0.00005411094,0.00005451095,0.0001466183,0.0001111986,0.00008148873,0.00002555725,0.000003750566,0.00008615374,2.893021e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001641186,"about_ca_system_score_gemma":0.0006107431,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000722827,"about_ca_topic_score_gemma":0.0001003173,"domain_scores_codex":[0.9990266,0.00002449624,0.0004352391,0.0000751406,0.0002946708,0.0001438678],"domain_scores_gemma":[0.9987973,0.0002286139,0.0003291892,0.000156288,0.0002897909,0.0001988251],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.04456924,0.000462465,0.01486897,0.0001992996,0.00145033,0.00007734124,0.01240694,0.00009923793,0.02467534,0.00001172903,0.08878027,0.8123989],"study_design_scores_gemma":[0.3402529,0.01902882,0.007276616,0.0007016069,0.00219337,0.0006185323,0.001142785,0.0006779204,0.01054188,0.00005561411,0.6173972,0.0001127137],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8672261,0.1024158,0.002716466,0.02359491,0.002055251,0.0007461062,0.000008374918,0.000006610934,0.001230442],"genre_scores_gemma":[0.9724122,0.01565502,0.0004999439,0.0006609772,0.007261263,0.00001297359,0.000003555032,0.00002203095,0.003472044],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8122861,"threshold_uncertainty_score":0.2222892,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2322121630","doi":"10.1056/nejm200103083441001","title":"Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis","year":2001,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Sepsis Diagnosis and Treatment","field":"Medicine","cited_by":6149,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital; University of Ottawa; Royal University Hospital","funders":"","keywords":"Drotrecogin alfa; Medicine; Placebo; Sepsis; Internal medicine; Clinical endpoint; Adverse effect; Randomized controlled trial; Surgery; Septic shock; Severe sepsis; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.06766904450525144,"gpt":0.3484623043665551,"spread":0.2807932598613037,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000519114,0.0001455365,0.0006627009,0.0001615712,0.00005501014,0.000003589251,0.00005616023,0.00006479913,0.0002077266],"category_scores_gemma":[0.0004000712,0.00008482439,0.00008356639,0.0001349064,0.00006615296,0.00005060997,0.00001133501,0.000161124,4.903483e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005377405,"about_ca_system_score_gemma":0.00007974826,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008299677,"about_ca_topic_score_gemma":0.00001290434,"domain_scores_codex":[0.9988049,0.00004488522,0.0005849238,0.0001227479,0.0002820502,0.0001605335],"domain_scores_gemma":[0.9987071,0.0002857565,0.0003849668,0.0001380366,0.0002181528,0.0002659821],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.0228814,0.002259324,0.09317882,0.0004085762,0.001882788,0.0005820318,0.002878098,0.00001394772,0.1324414,0.000680464,0.02610481,0.7166883],"study_design_scores_gemma":[0.4605359,0.02695328,0.2795069,0.006441913,0.001735144,0.003330941,0.0003949003,0.00001627491,0.02618437,0.001762045,0.1928746,0.0002637786],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9836495,0.001459623,0.0000812582,0.01346817,0.0001797753,0.0005949643,0.000001588131,0.000007423188,0.0005577125],"genre_scores_gemma":[0.9966716,0.0008388788,0.0007099236,0.0002102268,0.0008345086,0.000005296582,0.00001001282,0.00001735659,0.0007021925],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7164246,"threshold_uncertainty_score":0.3459038,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2171058244","doi":"10.1056/nejmoa1414905","title":"Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":6044,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Health Sciences Centre; London Health Sciences Centre; Toronto Western Hospital; Sunnybrook Health Science Centre; St. Michael's Hospital; Montreal Neurological Institute and Hospital; University of Toronto; University of Ottawa; Université de Montréal; University of Saskatchewan; University of Alberta; University of Calgary; Dalhousie University; Hotchkiss Brain Institute","funders":"","keywords":"Medicine; Modified Rankin Scale; Solitaire Cryptographic Algorithm; Collateral circulation; Randomized controlled trial; Occlusion; Stroke (engine); Odds ratio; Surgery; Internal medicine; Ischemia; Ischemic stroke","retraction":null,"screen_n_in":null,"score":{"opus":0.03374882398699773,"gpt":0.3130875912180942,"spread":0.2793387672310965,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002298581,0.0002258675,0.002052046,0.0003487922,0.00001034478,0.000002234257,0.0001473002,0.00006888119,0.0002757162],"category_scores_gemma":[0.0007225163,0.000127931,0.0003993944,0.0001592462,0.0002321505,0.00005718833,0.0000291847,0.0001834665,0.000001111811],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001790318,"about_ca_system_score_gemma":0.0004507449,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001152324,"about_ca_topic_score_gemma":0.000001531414,"domain_scores_codex":[0.99703,0.0001796212,0.001303722,0.0001434212,0.001147823,0.0001954405],"domain_scores_gemma":[0.9972844,0.0003916464,0.001056015,0.0003513533,0.0004969456,0.0004196872],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.205549,0.002014644,0.0182518,0.0005752199,0.01410647,0.001154797,0.00684528,0.0002178161,0.1539653,0.0003112564,0.2198055,0.3772028],"study_design_scores_gemma":[0.8217032,0.00551475,0.0004332728,0.000453929,0.002846685,0.0006764329,0.0006222714,0.0001922106,0.02024886,0.00002317213,0.1472015,0.00008377001],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8920588,0.01503286,0.009623171,0.006594195,0.0009510086,0.0009896503,0.00000687743,0.0000159846,0.07472743],"genre_scores_gemma":[0.983825,0.002962592,0.009219424,0.0001276311,0.00200387,0.000004969909,0.00001302472,0.00002214986,0.001821322],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6161541,"threshold_uncertainty_score":0.5216873,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2939222610","doi":"10.1056/nejmoa1811744","title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5996,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; University of British Columbia","funders":"Janssen Research and Development","keywords":"Canagliflozin; Medicine; Type 2 diabetes; Diabetes mellitus; Diabetic nephropathy; Nephropathy; Dapagliflozin; Internal medicine; Clinical trial; Type 2 Diabetes Mellitus; Endocrinology; Intensive care medicine; Pharmacology; Urology","retraction":null,"screen_n_in":null,"score":{"opus":0.009162856530291195,"gpt":0.2442398749127619,"spread":0.2350770183824707,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004219846,0.0001122323,0.0004821413,0.0002332925,0.00001082989,0.000007010987,0.0000364673,0.00003120857,0.000119992],"category_scores_gemma":[0.0001206351,0.00006550516,0.0000212293,0.0001065386,0.00004729424,0.00007058281,0.0000235351,0.0001454783,0.000003392727],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002802219,"about_ca_system_score_gemma":0.00004406065,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000810499,"about_ca_topic_score_gemma":0.00006590661,"domain_scores_codex":[0.9992234,0.00002814392,0.000278081,0.00009875742,0.0002171514,0.0001544268],"domain_scores_gemma":[0.9994446,0.0001142369,0.0001070535,0.00009071505,0.00004787401,0.0001955178],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002265558,0.00004483818,0.8697754,0.00006495821,0.0001612762,0.0001426996,0.0004846776,0.000001926442,0.001527577,0.000117254,0.002613127,0.1248397],"study_design_scores_gemma":[0.07211217,0.005100267,0.8583611,0.0008543032,0.0004451522,0.00009955551,0.0002904003,0.0000740603,0.0001768429,0.0005757191,0.06178724,0.0001231686],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9851967,0.004797038,0.000002530381,0.007912701,0.0003154145,0.0001547655,3.655233e-7,0.000004874653,0.001615589],"genre_scores_gemma":[0.9955014,0.001121332,0.0002419485,0.0009866284,0.0004384117,4.802176e-7,0.000002490779,0.000009419118,0.001697872],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1247166,"threshold_uncertainty_score":0.2671223,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2222086386","doi":"10.1056/nejmoa1510665","title":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5890,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Everolimus; Nivolumab; Renal cell carcinoma; Medicine; Oncology; Internal medicine; Cancer research; Urology; Immunotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.04492848070683175,"gpt":0.2874955900180906,"spread":0.2425671093112589,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008762554,0.0002386084,0.0007743814,0.0004172266,0.00002007935,0.00000581438,0.0001502347,0.00009025277,0.0001191667],"category_scores_gemma":[0.0005052601,0.0001582568,0.0001084578,0.0003210387,0.00007994611,0.000124162,0.00002856465,0.0005073398,0.00002121532],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000481791,"about_ca_system_score_gemma":0.0006443604,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003015018,"about_ca_topic_score_gemma":0.00009064068,"domain_scores_codex":[0.9977249,0.0001177366,0.0007478755,0.000198176,0.0008805997,0.0003306936],"domain_scores_gemma":[0.9979177,0.0002076241,0.0003580085,0.0002960914,0.0003301275,0.000890431],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1355054,0.001628702,0.1670995,0.0003140316,0.0004611571,0.04004299,0.01351457,0.001317098,0.05526497,0.0001187714,0.0762798,0.508453],"study_design_scores_gemma":[0.7852478,0.0399538,0.07513073,0.0008263507,0.0008120253,0.006029592,0.001609461,0.00012236,0.01731586,0.0004515149,0.07214421,0.0003563166],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9718586,0.007204995,0.00006960425,0.004089789,0.001134726,0.0002122379,9.245333e-7,0.00001191752,0.01541721],"genre_scores_gemma":[0.9941915,0.0001593342,0.001035545,0.0002356672,0.002651391,0.000001899968,0.000008754801,0.00002941583,0.001686454],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6497424,"threshold_uncertainty_score":0.6453525,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2120292596","doi":"10.1056/nejmoa040720","title":"Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer","year":2004,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5725,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"","keywords":"Prednisone; Mitoxantrone; Medicine; Docetaxel; Prostate cancer; Oncology; Internal medicine; Cancer; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.03697808835937899,"gpt":0.3596593328284429,"spread":0.3226812444690639,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006853042,0.0003407431,0.001137954,0.0003058113,0.000138016,0.00002063899,0.0002088275,0.0001198242,0.0003014173],"category_scores_gemma":[0.0005020251,0.0001852453,0.000165595,0.0003629898,0.000236666,0.0002313812,0.00003575438,0.0005078965,0.000005140439],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008930169,"about_ca_system_score_gemma":0.003253688,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002504863,"about_ca_topic_score_gemma":0.0001648311,"domain_scores_codex":[0.9971821,0.00004779117,0.0008609004,0.0003146768,0.0009424689,0.000652112],"domain_scores_gemma":[0.9975838,0.0002214426,0.0004818999,0.000276668,0.0006491006,0.0007870817],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2583257,0.000967663,0.003233971,0.001951977,0.002736846,0.003366605,0.01672462,0.0057308,0.07955432,0.0002627106,0.04138797,0.5857568],"study_design_scores_gemma":[0.7801051,0.02208224,0.002365065,0.00521046,0.001442388,0.002675677,0.001304016,0.0002338694,0.01884122,0.001515201,0.1638019,0.0004228724],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8209414,0.05916638,0.004900626,0.1081891,0.002415768,0.003451488,0.00009732864,0.00008320876,0.0007547077],"genre_scores_gemma":[0.932687,0.02313773,0.007569683,0.0009755599,0.01069531,0.0001248308,0.00006754069,0.0001078918,0.0246344],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5853339,"threshold_uncertainty_score":0.7554083,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2787301955","doi":"10.1056/nejmoa1709866","title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5641,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hospital for Sick Children; Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Lymphoblastic Leukemia; Medicine; Leukemia; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.008970916473494756,"gpt":0.2580174046244769,"spread":0.2490464881509822,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007485023,0.0001644597,0.0004783413,0.0003559602,0.00003616726,0.00001029158,0.0001143665,0.00007123092,0.001037408],"category_scores_gemma":[0.0001772277,0.00009854275,0.0000311583,0.0002964392,0.0002912947,0.00007583806,0.00002446688,0.0004217398,0.000008140611],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000172032,"about_ca_system_score_gemma":0.0004433873,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006502065,"about_ca_topic_score_gemma":0.0002833824,"domain_scores_codex":[0.9984068,0.00006961104,0.0004155744,0.0001764182,0.0006447802,0.0002867734],"domain_scores_gemma":[0.9988749,0.0001229044,0.000166079,0.0001786892,0.0002205353,0.0004368801],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01994646,0.000186928,0.503536,0.0001065777,0.0002472322,0.001104037,0.006881388,0.000007506688,0.0700179,0.00001471024,0.007882032,0.3900692],"study_design_scores_gemma":[0.3168774,0.01970884,0.6209462,0.002458517,0.000288554,0.02575346,0.0004982126,0.0002952302,0.006135383,0.0001335618,0.006650976,0.0002536392],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926869,0.001588785,0.0001586982,0.00107545,0.0001631842,0.0002267123,9.671351e-7,0.000008426132,0.004090901],"genre_scores_gemma":[0.9914851,0.0008854503,0.0003786037,0.0002907307,0.004197399,8.530593e-7,0.000003623548,0.00002842769,0.002729878],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3898156,"threshold_uncertainty_score":0.9998758,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2119472226","doi":"10.1056/nejmsa0810119","title":"A Surgical Safety Checklist to Reduce Morbidity and Mortality in a Global Population","year":2009,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Patient Safety and Medication Errors","field":"Health Professions","cited_by":5607,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Checklist; Health care; Tanzania; Mortality rate; Population; Patient safety; Emergency medicine; Pediatrics; Surgery; Environmental health","retraction":null,"screen_n_in":null,"score":{"opus":0.06885417744852244,"gpt":0.4485239990241824,"spread":0.3796698215756599,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002140022,0.00009232653,0.000363779,0.00009604356,0.00009738714,4.180237e-7,0.00008649667,0.00009472484,0.0001243104],"category_scores_gemma":[0.001066676,0.00006361429,0.00002504278,0.0002756263,0.00003291732,0.00009246819,0.00001487622,0.0004372372,0.00000376337],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001725921,"about_ca_system_score_gemma":0.0001915712,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009654562,"about_ca_topic_score_gemma":0.0006611111,"domain_scores_codex":[0.9981192,0.000339125,0.0008242503,0.0001151383,0.0003961739,0.0002061227],"domain_scores_gemma":[0.9987729,0.0001683462,0.0003822722,0.0001120222,0.0001012435,0.0004632725],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001850409,0.00009084311,0.9166504,0.00003573528,0.0000157023,0.000110949,0.004157275,0.0001003805,0.0000727742,0.001670486,0.004330209,0.07091489],"study_design_scores_gemma":[0.01794518,0.0003823941,0.9394541,0.0004963196,0.00002504565,0.00008172156,0.000302194,0.00003050796,0.000001539877,0.001548147,0.03967866,0.00005423512],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9515412,0.0002204239,0.0006927088,0.04321869,0.0006801274,0.0002181967,0.000004656948,0.000008969353,0.003415031],"genre_scores_gemma":[0.9959734,0.0001477702,0.0002114727,0.001430201,0.002045457,0.000001027704,0.00001147343,0.000002843299,0.0001763668],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07086066,"threshold_uncertainty_score":0.2594115,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2767776410","doi":"10.1056/nejmoa1706442","title":"Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":5539,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Toronto Western Hospital; University of Toronto; University Health Network; Capital District Health Authority","funders":"David Geffen School of Medicine, University of California, Los Angeles; Abbott Vascular; University at Buffalo; Genentech; University of California, Los Angeles; Servier; Kaiser Permanente; University of Toronto; Rush University; University of California, San Francisco; Universitat Autònoma de Barcelona; Boston Scientific Corporation; Bristol-Myers Squibb; University of Miami; AstraZeneca; Pfizer; University of Tennessee at Chattanooga; Leonard M. Miller School of Medicine; Stryker; JFK Medical Center Foundation","keywords":"Medicine; Neurological deficit; Stroke (engine); Cardiology; Ischemic stroke; Internal medicine; Infarction; Anesthesia; Myocardial infarction; Ischemia","retraction":null,"screen_n_in":null,"score":{"opus":0.01961078097563677,"gpt":0.2821728169425383,"spread":0.2625620359669015,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005975698,0.0002147907,0.0007101131,0.0002257947,0.00008667717,0.0000358843,0.0002236589,0.00006218639,0.0001758131],"category_scores_gemma":[0.0003490087,0.0001243211,0.00005171021,0.00006342578,0.0001666278,0.0001269082,0.00009774837,0.0004109333,0.000006633763],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005050367,"about_ca_system_score_gemma":0.0001103913,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001636299,"about_ca_topic_score_gemma":0.00004388407,"domain_scores_codex":[0.9984246,0.00002607715,0.0004171744,0.0001877112,0.000671784,0.0002726194],"domain_scores_gemma":[0.9982974,0.0001139835,0.000374893,0.0004319372,0.0001627721,0.0006190329],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001973037,0.00003261311,0.8639302,0.0000697014,0.0006214871,0.001061398,0.001697922,0.000001720263,0.001573077,0.000007909396,0.0434508,0.08558009],"study_design_scores_gemma":[0.05207346,0.003884345,0.8065061,0.00162184,0.00126549,0.001614825,0.0004429903,0.000002607263,0.0006377932,0.00003276132,0.1317397,0.0001780326],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9549776,0.0006512874,0.00133487,0.03600595,0.0002372154,0.0002537821,0.000004810548,0.00001166296,0.006522794],"genre_scores_gemma":[0.9887937,0.0001422122,0.004187683,0.001221091,0.003704106,0.000002869124,0.000002110957,0.00002795038,0.00191832],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08828894,"threshold_uncertainty_score":0.5069666,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2138297714","doi":"10.1056/nejmoa050753","title":"Erlotinib in Previously Treated Non–Small-Cell Lung Cancer","year":2005,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5451,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research; Hotel Dieu Shaver Health and Rehabilitation Centre; Princess Margaret Cancer Centre; University Health Network; University of Toronto; McGill University","funders":"National Cancer Institute","keywords":"Erlotinib; Medicine; Lung cancer; Hazard ratio; Internal medicine; Erlotinib Hydrochloride; Chemotherapy; Randomization; Placebo; Performance status; Oncology; Surgery; Epidermal growth factor receptor; Gastroenterology; Cancer; Randomized controlled trial; Confidence interval; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.0143240950170995,"gpt":0.3292720035477968,"spread":0.3149479085306973,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003205199,0.000152865,0.0004871678,0.000249441,0.00002832516,0.00000582427,0.00007685786,0.00005766295,0.000611259],"category_scores_gemma":[0.00006746814,0.00009287093,0.0000672551,0.0002341144,0.0000326378,0.00008057413,0.000007932216,0.0002845899,0.000004648884],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002742593,"about_ca_system_score_gemma":0.000509307,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008503137,"about_ca_topic_score_gemma":0.000737317,"domain_scores_codex":[0.9987895,0.00003592957,0.0005432405,0.000124608,0.0002789742,0.0002277874],"domain_scores_gemma":[0.9990606,0.00008234906,0.0002481028,0.0001274581,0.0001548121,0.0003266916],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.001313531,0.0005644912,0.5322969,0.0001970101,0.000477807,0.0008718219,0.01105291,0.0006414033,0.004474779,0.00002120555,0.03978077,0.4083073],"study_design_scores_gemma":[0.4522726,0.005619603,0.2379692,0.006142143,0.005124988,0.002344217,0.0008528337,0.001321733,0.004309927,0.00007606537,0.2835312,0.0004355007],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9609581,0.01298261,0.0001676345,0.01758846,0.0003386611,0.0004407687,0.000002341187,0.00001241477,0.007508975],"genre_scores_gemma":[0.9853162,0.002410377,0.0008931273,0.001042188,0.004367189,0.000008697659,0.00000843373,0.00002227689,0.005931521],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4509591,"threshold_uncertainty_score":0.6692857,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2753432434","doi":"10.1056/nejmoa1709684","title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5392,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Ipilimumab; Nivolumab; Medicine; Melanoma; Oncology; Internal medicine; Overall survival; Metastatic melanoma; Clinical trial; Immunotherapy; Cancer; Cancer research","retraction":null,"screen_n_in":null,"score":{"opus":0.01592681096580529,"gpt":0.2789838467585548,"spread":0.2630570357927495,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000666388,0.0001431115,0.0005620643,0.0001415277,0.00007899645,0.00001812427,0.0001333875,0.00005300195,0.0001015259],"category_scores_gemma":[0.0001707382,0.00008419625,0.00004016894,0.00005114255,0.0002096577,0.0001574883,0.0000182145,0.0002903243,5.196884e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006053952,"about_ca_system_score_gemma":0.0001800242,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004640963,"about_ca_topic_score_gemma":0.0005175115,"domain_scores_codex":[0.9989033,0.00004111908,0.0003892347,0.0001253152,0.0003648155,0.0001762405],"domain_scores_gemma":[0.9989516,0.00009715693,0.0003896134,0.0002594485,0.000103061,0.0001991918],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1052024,0.0001933644,0.3421039,0.000115902,0.0004296608,0.001733353,0.001842641,0.000004853407,0.02062057,0.0001678825,0.002617386,0.524968],"study_design_scores_gemma":[0.3370108,0.008938366,0.6307694,0.001402736,0.0001268012,0.001722102,0.0002374611,0.00002372764,0.0004808143,0.0002794832,0.01887976,0.0001285886],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9813718,0.002229005,0.00004694268,0.01313378,0.0004736679,0.0001414866,8.948343e-7,0.000005801134,0.002596607],"genre_scores_gemma":[0.9962611,0.001345722,0.0003458069,0.0003381819,0.0009312191,7.30726e-7,0.000001904801,0.00001504956,0.000760324],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5248395,"threshold_uncertainty_score":0.3433423,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2128035403","doi":"10.1056/nejmoa1412082","title":"Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5352,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Royal Victoria Hospital; BC Cancer Agency","funders":"","keywords":"Nivolumab; Melanoma; Mutation; Medicine; Cancer research; Biology; Genetics; Internal medicine; Cancer; Immunotherapy; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.007510965650476341,"gpt":0.2337536327064622,"spread":0.2262426670559859,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000690329,0.0001163396,0.0002651505,0.00009567281,0.00002078341,0.00000601595,0.000127858,0.00008492848,0.00003687906],"category_scores_gemma":[0.0003523449,0.00008141409,0.00004070977,0.00008025477,0.00004194567,0.000005419823,0.00001602342,0.0001321502,0.000003573893],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001301641,"about_ca_system_score_gemma":0.00009131656,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007931194,"about_ca_topic_score_gemma":0.0002255187,"domain_scores_codex":[0.9990199,0.0001343741,0.0003776746,0.0001260449,0.0001804025,0.0001616178],"domain_scores_gemma":[0.9993515,0.00003053774,0.0002248204,0.0001448877,0.00009346887,0.0001548038],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001881538,0.0001269173,0.09006483,0.0000633016,0.0001243753,0.0002426277,0.001319857,0.0002210656,0.4466833,0.0002523715,0.01600127,0.4430185],"study_design_scores_gemma":[0.2167009,0.03622241,0.05128434,0.00101824,0.000324874,0.0072732,0.0003703437,0.0005501881,0.1266525,0.002560381,0.5562831,0.0007594659],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921202,0.0009757536,0.002882851,0.0007961017,0.0003298967,0.00008358491,7.371794e-7,0.000004047619,0.002806837],"genre_scores_gemma":[0.9960175,0.0001661948,0.0003792318,0.0003310781,0.002530392,9.744093e-7,0.00002383771,0.00001298728,0.0005377925],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5402818,"threshold_uncertainty_score":0.331997,"prediction_status":"machine_predicted_unvalidated"},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2328786770","doi":"10.1056/nejm200007273430401","title":"Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen","year":2000,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":5268,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Capital Power (Canada); University of Alberta","funders":"","keywords":"Medicine; Transplantation; Internal medicine; Endocrinology; Hypoglycemia; Diabetes mellitus; Insulin; Gastroenterology; Pancreas transplantation; Islet; Urology; Kidney transplantation","retraction":null,"screen_n_in":null,"score":{"opus":0.009860819254215818,"gpt":0.2364329094640012,"spread":0.2265720902097854,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000281245,0.0001434858,0.0005129856,0.0002040647,0.00002356167,0.000006517225,0.00008502383,0.00005774319,0.0009879152],"category_scores_gemma":[0.000210223,0.00008757818,0.00003708121,0.0002693459,0.00005920493,0.0001357433,0.000004282881,0.000239748,0.000006607178],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006163774,"about_ca_system_score_gemma":0.0001621718,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007751458,"about_ca_topic_score_gemma":0.000004359179,"domain_scores_codex":[0.9986746,0.00007609271,0.0004838159,0.0001175877,0.0004475714,0.00020031],"domain_scores_gemma":[0.9990625,0.00018294,0.0002169383,0.0001844587,0.0001840153,0.0001691029],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02619035,0.0007210929,0.7098032,0.0004379936,0.0008434644,0.000648552,0.01059091,0.00164719,0.02867046,0.00002518729,0.005655124,0.2147665],"study_design_scores_gemma":[0.3814676,0.01304821,0.5725713,0.007447412,0.002034465,0.0006014828,0.0005398444,0.0009911277,0.006844346,0.0005799227,0.01341901,0.0004553695],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995064,0.001993879,0.00003551043,0.0009312436,0.000226013,0.000204666,0.000003581212,0.000007979563,0.001533104],"genre_scores_gemma":[0.996987,0.0007072749,0.0007433564,0.0005366386,0.0006392897,5.33595e-7,0.00002989103,0.00001745191,0.0003385573],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3552772,"threshold_uncertainty_score":0.9999253,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2037399775","doi":"10.1056/nejmoa1415061","title":"Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":5130,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Toronto Western Hospital; University of Toronto; University Health Network; University of Calgary","funders":"","keywords":"Medicine; Stroke (engine); Stent; Cardiology; Internal medicine; Anesthesia","retraction":null,"screen_n_in":null,"score":{"opus":0.01987982761722756,"gpt":0.2653737862657271,"spread":0.2454939586484995,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001462,0.0002759984,0.000989206,0.0005027161,0.00001630585,0.00001186193,0.0002199087,0.0001197625,0.0005262019],"category_scores_gemma":[0.0007655259,0.0001829753,0.0001061168,0.0003495105,0.0001417163,0.0001546765,0.00007930744,0.0007791718,0.00003101366],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002978369,"about_ca_system_score_gemma":0.0003299976,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002237907,"about_ca_topic_score_gemma":0.00005611232,"domain_scores_codex":[0.997123,0.00008807992,0.0009351864,0.0002259538,0.001210279,0.0004175132],"domain_scores_gemma":[0.9980931,0.0001334683,0.0003727229,0.0003281736,0.0003251793,0.0007473944],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.02476298,0.0008657601,0.2930872,0.0002531298,0.001158538,0.0180834,0.01165553,0.00006846552,0.0071724,0.00007081837,0.4545131,0.1883086],"study_design_scores_gemma":[0.2472425,0.008062425,0.1162479,0.001708757,0.001038334,0.006002728,0.001941748,0.0001087819,0.001833851,0.0001947314,0.6152363,0.0003819255],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9605317,0.003659922,0.001148489,0.02116,0.001337217,0.0003640263,0.000004456035,0.00002293964,0.01177123],"genre_scores_gemma":[0.9867317,0.0003710058,0.001677643,0.002482341,0.005005651,0.000003146405,0.000008739936,0.00003700327,0.003682744],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2224795,"threshold_uncertainty_score":0.7461514,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2096246254","doi":"10.1056/nejmoa1310907","title":"Edoxaban versus Warfarin in Patients with Atrial Fibrillation","year":2013,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":5126,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; Women's College Hospital","funders":"Biosense Webster; St. Jude Medical; Eisai; Janssen Scientific Affairs; Daiichi Sankyo Europe; Sanofi; Bayer HealthCare; Medicines Company; Boston Scientific Corporation; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; AtriCure; Janssen Pharmaceuticals; Gilead Sciences; Pfizer","keywords":"Edoxaban; Atrial fibrillation; Warfarin; Medicine; Cardiology; Internal medicine; Rivaroxaban","retraction":null,"screen_n_in":null,"score":{"opus":0.03519064614790252,"gpt":0.2958072714181509,"spread":0.2606166252702484,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003240272,0.0001135855,0.0003975578,0.0002817217,0.00002119011,0.000009709448,0.00004977711,0.00004594282,0.0005783947],"category_scores_gemma":[0.0004111359,0.00006537051,0.00007425181,0.0002224075,0.00003579024,0.0001952998,0.00001293929,0.0001525874,0.00001679041],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005941783,"about_ca_system_score_gemma":0.00006776894,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001354502,"about_ca_topic_score_gemma":0.00002096774,"domain_scores_codex":[0.9987217,0.00004266078,0.0004848849,0.00008916115,0.0005200977,0.0001415029],"domain_scores_gemma":[0.999045,0.0001992238,0.0002822867,0.0001039049,0.0001976335,0.0001719909],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00602422,0.000003142185,0.8619295,0.00001255632,0.0000929129,0.000010954,0.0002101851,0.000208074,0.00002382613,0.00006418322,0.002054903,0.1293655],"study_design_scores_gemma":[0.1568531,0.002759254,0.8111871,0.0001555294,0.0001630269,0.0000109177,0.00006093747,0.00006353568,0.000007437962,0.0001149917,0.02855637,0.00006778954],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9868096,0.0002066967,0.0001276699,0.01021301,0.0009334245,0.0003343546,2.371416e-7,0.000009488722,0.001365582],"genre_scores_gemma":[0.9884205,0.00005701157,0.0005744184,0.00008043657,0.01032641,5.956111e-8,0.00001159374,0.00001185657,0.0005177056],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1508289,"threshold_uncertainty_score":0.6333017,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2149908785","doi":"10.1056/nejmoa052306","title":"Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer","year":2005,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5098,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; McGill University","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Chemotherapy; Adjuvant; Monoclonal antibody; Internal medicine; Adjuvant chemotherapy; Cancer; Stage (stratigraphy); Antibody; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.01611926741677746,"gpt":0.3460186708027299,"spread":0.3298994033859524,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001029087,0.0001968168,0.0006922761,0.0003570738,0.00002122357,0.000008737885,0.000152692,0.000094805,0.004447939],"category_scores_gemma":[0.00009502105,0.0001259977,0.0000886556,0.0003301532,0.000146798,0.0001160255,0.0000159682,0.0008395786,0.00001431477],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005802396,"about_ca_system_score_gemma":0.0007310237,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007359544,"about_ca_topic_score_gemma":0.0006600738,"domain_scores_codex":[0.9977418,0.0001060042,0.0006541754,0.0001848242,0.0009270871,0.0003861446],"domain_scores_gemma":[0.9987222,0.0001088862,0.0001777487,0.0001819258,0.0002907169,0.0005184981],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.007043089,0.0002360957,0.06269674,0.0000623342,0.0001330964,0.0011045,0.004351454,0.00003782617,0.002915669,0.000008362491,0.01939628,0.9020146],"study_design_scores_gemma":[0.1114031,0.002710029,0.6978382,0.004178235,0.0001497742,0.007013271,0.0003904518,0.0001491506,0.001575368,0.0001020602,0.1742733,0.0002171056],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8134167,0.01076033,0.0001550208,0.1728565,0.0004362177,0.000306902,0.00001413573,0.00001196594,0.002042259],"genre_scores_gemma":[0.9793025,0.004123266,0.0003886745,0.00394812,0.01110412,0.000007923018,0.000002353673,0.00003704003,0.001085988],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9017975,"threshold_uncertainty_score":0.9964621,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2145053281","doi":"10.1056/nejmoa0810625","title":"Intensive versus Conventional Glucose Control in Critically Ill Patients","year":2009,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hyperglycemia and glycemic control in critically ill and hospitalized patients","field":"Medicine","cited_by":5097,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"University of Alberta","keywords":"Medicine; Liter; Critically ill; Intensive care unit; Randomization; Intensive care; Target range; Randomized controlled trial; Intensive care medicine; Anesthesia; Emergency medicine; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.01604647058486143,"gpt":0.294125931513564,"spread":0.2780794609287026,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004039212,0.0001846292,0.0007305357,0.0002540455,0.00003200615,0.00000785919,0.0001141852,0.0001088266,0.000384114],"category_scores_gemma":[0.007722024,0.000125375,0.0001449576,0.0001525803,0.0001343074,0.0001075705,0.000008681062,0.0005073125,0.000009530754],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008826624,"about_ca_system_score_gemma":0.0001874913,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002372182,"about_ca_topic_score_gemma":0.000006916851,"domain_scores_codex":[0.9979219,0.0000756286,0.0008708742,0.0001601903,0.0006601128,0.0003112338],"domain_scores_gemma":[0.9947519,0.0004236435,0.0001628252,0.0001320739,0.004010702,0.000518818],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1472198,0.002620231,0.153459,0.0001164667,0.0006616646,0.004176817,0.002409277,0.00002306712,0.007058531,0.007176417,0.04373108,0.6313477],"study_design_scores_gemma":[0.7628928,0.03057519,0.1445077,0.001457117,0.0007308295,0.0006351875,0.0005606943,0.0002773938,0.0001004455,0.004161438,0.05381788,0.000283268],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9229417,0.001291938,0.001216058,0.06783926,0.001952985,0.000297434,0.000007228509,0.00001372141,0.004439623],"genre_scores_gemma":[0.9733351,0.0001555436,0.0003045686,0.02427662,0.001772641,9.765123e-7,0.00001701361,0.000009785554,0.0001277256],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6310644,"threshold_uncertainty_score":0.9244542,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3081830235","doi":"10.1056/nejmoa2022190","title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5037,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Boehringer Ingelheim (Canada); University of Toronto; McGill University Health Centre; St. Michael's Hospital","funders":"Eli Lilly and Company; Boehringer Ingelheim","keywords":"Empagliflozin; Heart failure; Medicine; Ejection fraction; Cardiology; Diabetes mellitus; Internal medicine; Benzhydryl compounds; Broad spectrum; Heart failure with preserved ejection fraction; Type 2 diabetes; Endocrinology; Chemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.01415884499992119,"gpt":0.236561217026782,"spread":0.2224023720268609,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003730367,0.0001278687,0.0006850854,0.0001325831,0.00001378832,0.000006433886,0.00004463607,0.00002857325,0.00006264349],"category_scores_gemma":[0.0001147694,0.00006717023,0.00008088743,0.0001576237,0.00005102872,0.00006794395,0.00001622957,0.0002046426,0.000002160565],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000216377,"about_ca_system_score_gemma":0.00005321517,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003844828,"about_ca_topic_score_gemma":0.00002692061,"domain_scores_codex":[0.9989972,0.00003913396,0.000278711,0.0001168507,0.0004264011,0.0001417128],"domain_scores_gemma":[0.9993855,0.00005282484,0.00007455696,0.0001039447,0.00005141409,0.0003316967],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001549885,0.0001095821,0.8494911,0.0001715763,0.002645425,0.002392239,0.0026037,0.0001258773,0.0007858808,0.00009619696,0.04426388,0.09576467],"study_design_scores_gemma":[0.1568662,0.007108022,0.2366066,0.0008757188,0.001934012,0.000615188,0.0006808977,0.00003785524,0.0002545254,0.00008782508,0.5947765,0.0001567163],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8578954,0.004708061,0.000266842,0.1361838,0.00007706907,0.000212208,4.772132e-7,0.0000117281,0.0006444458],"genre_scores_gemma":[0.9937358,0.000215338,0.002204399,0.002606008,0.001059465,0.000001068273,0.000002516586,0.00001272131,0.0001627175],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6128845,"threshold_uncertainty_score":0.2739123,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2159449551","doi":"10.1056/nejmoa040583","title":"Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes","year":2004,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":4942,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"Bristol-Myers Squibb","keywords":"Medicine; Atorvastatin; Pravastatin; Hazard ratio; Acute coronary syndrome; Unstable angina; Myocardial infarction; Liter; Internal medicine; Confidence interval; Regimen; Clinical endpoint; Statin; Cardiology; Cholesterol; Randomized controlled trial","retraction":null,"screen_n_in":null,"score":{"opus":0.01850458348222359,"gpt":0.2717493932242229,"spread":0.2532448097419993,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005200318,0.0001995523,0.0007465488,0.0001647078,0.00004629632,0.000009597518,0.00007793667,0.00006130949,0.0001185099],"category_scores_gemma":[0.0001491322,0.0001126973,0.0001302694,0.0001584557,0.0001067528,0.0001334651,0.00002033891,0.0005053135,0.000005739478],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001522969,"about_ca_system_score_gemma":0.0005737448,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00019404,"about_ca_topic_score_gemma":0.00005522566,"domain_scores_codex":[0.9982995,0.00003687712,0.0004413118,0.0001606631,0.0007846344,0.0002769936],"domain_scores_gemma":[0.9984156,0.00005389254,0.000207098,0.0002526989,0.0005567665,0.0005139234],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2047956,0.0004848675,0.01049656,0.0007999754,0.01331329,0.1114535,0.02149447,0.002807553,0.004126109,0.0002074438,0.003871666,0.6261489],"study_design_scores_gemma":[0.6831381,0.05797423,0.07724281,0.008778239,0.005583242,0.1366141,0.003691532,0.00006573594,0.003240692,0.0007417074,0.02221566,0.0007139142],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.981032,0.002549705,0.006109274,0.008939137,0.0008269143,0.000226468,0.000002879851,0.00001788331,0.0002958108],"genre_scores_gemma":[0.9920427,0.001315549,0.0019018,0.001370396,0.003161731,0.000003073625,0.000005520512,0.0000323582,0.0001668989],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.625435,"threshold_uncertainty_score":0.4595661,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2787867590","doi":"10.1056/nejmoa1713973","title":"Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":4824,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"National Center for Advancing Translational Sciences; National Institute of Neurological Disorders and Stroke","keywords":"Stroke (engine); Selection (genetic algorithm); Perfusion scanning; Medicine; Perfusion; Cardiology; Internal medicine; Computer science; Artificial intelligence; Engineering; Mechanical engineering","retraction":null,"screen_n_in":null,"score":{"opus":0.009331825754751721,"gpt":0.2713136573158571,"spread":0.2619818315611054,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005711654,0.0001650395,0.0004065091,0.0002197687,0.00008610891,0.0000078036,0.00009957568,0.00003475685,0.0004222773],"category_scores_gemma":[0.0002196082,0.00009843391,0.00005300055,0.0001787529,0.00008850134,0.00007491269,0.00003389545,0.0001843745,0.000007208703],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002879387,"about_ca_system_score_gemma":0.00009017347,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007340078,"about_ca_topic_score_gemma":0.00005335312,"domain_scores_codex":[0.9986493,0.00002285668,0.0003479595,0.000175276,0.0005454156,0.0002591958],"domain_scores_gemma":[0.9987674,0.00009550137,0.0002431076,0.0001340227,0.0003983397,0.0003616048],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003332714,0.00003772136,0.03003902,0.00002338097,0.0001152402,0.0000244971,0.0006506962,0.000002337936,0.124578,0.000004012216,0.7633144,0.07787795],"study_design_scores_gemma":[0.0688528,0.01055317,0.005780577,0.0009035191,0.0007640361,0.002563723,0.0005850979,0.0001325108,0.04742971,0.00001471405,0.8622485,0.0001716653],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9032745,0.0005138857,0.05763089,0.03055121,0.0005555925,0.0004827885,0.000004360427,0.00002737115,0.006959413],"genre_scores_gemma":[0.9758337,0.00006538765,0.005921269,0.002825976,0.007692565,0.000003865102,0.00001137705,0.00003512149,0.007610719],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09893402,"threshold_uncertainty_score":0.4623641,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2921388585","doi":"10.1056/nejmoa1814052","title":"Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cardiac Valve Diseases and Treatments","field":"Medicine","cited_by":4758,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; Université Laval","funders":"Edwards Lifesciences","keywords":"Medicine; Valve replacement; Stenosis; Aortic valve replacement; Cardiology; Internal medicine; Aortic valve stenosis; Balloon; Surgery; Aortic valve","retraction":null,"screen_n_in":null,"score":{"opus":0.005969137467521982,"gpt":0.2703818423186118,"spread":0.2644127048510899,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004628364,0.0002248429,0.0007349959,0.0002292834,0.00002450254,0.000008833508,0.00007838973,0.0000572931,0.0006261742],"category_scores_gemma":[0.00009635808,0.0001266202,0.0007916221,0.0001912169,0.00004249435,0.0001024335,0.00001164967,0.0003170228,0.0000215408],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001350707,"about_ca_system_score_gemma":0.0001983298,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002226533,"about_ca_topic_score_gemma":0.00001405435,"domain_scores_codex":[0.9980331,0.00007549451,0.0005984312,0.0002159401,0.0007854474,0.0002915936],"domain_scores_gemma":[0.9986227,0.0001030475,0.0003434194,0.0002743595,0.0002200623,0.0004364778],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005782139,0.0005816942,0.9697204,0.00008071516,0.001611196,0.00002573322,0.001124054,0.00006099529,0.00004207707,0.000004657943,0.0006583097,0.02030798],"study_design_scores_gemma":[0.159915,0.008706151,0.8244553,0.001627112,0.002300737,0.00009871057,0.000253034,0.00003215828,0.00005438157,0.0000693277,0.002353478,0.0001345669],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956573,0.001457409,0.00007968589,0.000524077,0.0004153804,0.0004968025,0.000009596971,0.000008437874,0.001351278],"genre_scores_gemma":[0.9978488,0.0004964631,0.0001559657,0.0003928236,0.0006184588,0.000004076326,0.00002533622,0.00002891072,0.0004291594],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1541329,"threshold_uncertainty_score":0.6856169,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2160414137","doi":"10.1056/nejmoa070829","title":"Optimal Medical Therapy with or without PCI for Stable Coronary Disease","year":2007,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Acute Myocardial Infarction Research","field":"Medicine","cited_by":4694,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Conventional PCI; Percutaneous coronary intervention; Medical therapy; Coronary artery disease; Cardiology; Internal medicine; Disease; Coronary disease; Intensive care medicine; Coronary heart disease; Myocardial infarction","retraction":null,"screen_n_in":null,"score":{"opus":0.04636184424055105,"gpt":0.3709223157641374,"spread":0.3245604715235864,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003162223,0.0001901184,0.0006735287,0.0002785605,0.00008062999,0.000009577947,0.0001837887,0.00009505606,0.001669013],"category_scores_gemma":[0.001198616,0.00009161139,0.00009935055,0.0002532962,0.000286939,0.000114683,0.00002099529,0.0005907014,0.000003996717],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008952367,"about_ca_system_score_gemma":0.001565759,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006809884,"about_ca_topic_score_gemma":0.00001802711,"domain_scores_codex":[0.9969771,0.00006602543,0.0006055392,0.0001746156,0.00175632,0.0004203997],"domain_scores_gemma":[0.9963801,0.0006945119,0.0002270653,0.0002194482,0.0006332129,0.001845652],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.2674612,0.0004976708,0.09640771,0.0001323453,0.00123334,0.007298222,0.001011406,0.00005976839,0.001381744,0.0001179731,0.1922937,0.4321049],"study_design_scores_gemma":[0.1689751,0.01671779,0.02132773,0.0007363575,0.000335562,0.01092207,0.0005350672,0.0003877922,0.0003407839,0.00006527292,0.7794842,0.0001722551],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7434707,0.004960224,0.09943596,0.1474356,0.001029111,0.001436633,0.00001143763,0.00005837884,0.002161966],"genre_scores_gemma":[0.949545,0.002776119,0.01124469,0.01434161,0.01588468,0.000009335822,0.00002776966,0.00008004706,0.006090739],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5871906,"threshold_uncertainty_score":0.9992436,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2792937256","doi":"10.1056/nejmoa1712126","title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4643,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; University Hospital Foundation","funders":"Foundation Medicine; Kite Pharma; Genentech; Astellas Pharma; Eisai; Jounce Therapeutics; Takeda Oncology; Mirati Therapeutics; Acceleron; Clovis Oncology; BioMarin Pharmaceutical; Mylan; Celldex Therapeutics; Taiho Pharmaceutical; Horizon Pharma; Ipsen; Array BioPharma; Bayer HealthCare; Exelixis; Sanofi; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Amgen; INOVIO Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; LEO Pharma; Intuitive Surgical; Pfizer; EUSA Pharma; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ipilimumab; Sunitinib; Nivolumab; Renal cell carcinoma; Medicine; Internal medicine; Oncology; Cancer research; Urology; Immunotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.03398449636464475,"gpt":0.2907462659043244,"spread":0.2567617695396797,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007527765,0.0002940583,0.0008897029,0.0005284231,0.00005671565,0.000008408864,0.0001946574,0.0001107143,0.0006536747],"category_scores_gemma":[0.0004174957,0.0002005127,0.0001345503,0.0004172734,0.0002342853,0.000129112,0.00003797627,0.0005778717,0.00003678851],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005023701,"about_ca_system_score_gemma":0.0006501624,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003131734,"about_ca_topic_score_gemma":0.0002442287,"domain_scores_codex":[0.9974868,0.0001356926,0.0008957756,0.0002560385,0.0007959013,0.0004298174],"domain_scores_gemma":[0.9978089,0.000336862,0.0004351226,0.0003789301,0.0004384562,0.000601779],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1686357,0.001238866,0.03992461,0.0004272787,0.0005280706,0.02235204,0.01458255,0.0001542305,0.1368054,0.000232115,0.02881962,0.5862995],"study_design_scores_gemma":[0.7383662,0.05428392,0.06520575,0.001363849,0.0008865368,0.00514818,0.001664263,0.0001623632,0.05151262,0.0002593711,0.08071969,0.0004271917],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9656729,0.003014408,0.00009611647,0.003134568,0.001283514,0.0002704855,0.000001811089,0.00001619222,0.02650998],"genre_scores_gemma":[0.9900785,0.0002082062,0.0009980556,0.0002916364,0.005856327,0.000002426879,0.00001363755,0.000039567,0.002511621],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5858724,"threshold_uncertainty_score":0.817667,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2138871107","doi":"10.1056/nejmoa1402584","title":"Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":4611,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University","funders":"Genentech; Shionogi; Imperial College London; National Institute for Health and Care Research; Veracyte; Galecto; Massachusetts Medical Society; Royal Brompton and Harefield NHS Foundation Trust; University Hospital Southampton NHS Foundation Trust; Gilead Sciences; FibroGen; Biogen; Ikaria; Celgene; Sanofi; Amgen; Pfizer; GlaxoSmithKline","keywords":"Nintedanib; Medicine; Idiopathic pulmonary fibrosis; Placebo; Exacerbation; Vital capacity; Internal medicine; Clinical endpoint; Gastroenterology; Clinical trial; Pathology; Lung; Lung function","retraction":null,"screen_n_in":null,"score":{"opus":0.009888083905451041,"gpt":0.2541277349581891,"spread":0.244239651052738,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001269734,0.0001676594,0.0008006243,0.0003053122,0.00002776543,0.000003876344,0.0001075314,0.00009049086,0.00009121373],"category_scores_gemma":[0.000780223,0.0001129066,0.00009978354,0.0002037237,0.0001843635,0.00008929082,0.00003158268,0.0003935881,0.00000152325],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000043684,"about_ca_system_score_gemma":0.0001332431,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001359127,"about_ca_topic_score_gemma":0.00000625515,"domain_scores_codex":[0.9981962,0.0001468694,0.0008801376,0.0001518807,0.0004292135,0.0001957354],"domain_scores_gemma":[0.9987022,0.0002294566,0.0003532967,0.0001722737,0.0001745955,0.0003681405],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1278041,0.000900833,0.06060459,0.001676416,0.0002862084,0.001368156,0.003392396,0.00007819429,0.1393855,0.002064,0.002276638,0.660163],"study_design_scores_gemma":[0.2314175,0.07442573,0.55255,0.04274511,0.00190035,0.01569816,0.001224575,0.002617551,0.002383526,0.003477562,0.07084573,0.0007141787],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9740232,0.01212596,0.0009148007,0.007246673,0.0005764147,0.0002503918,0.000005154352,0.00001301035,0.004844422],"genre_scores_gemma":[0.995466,0.001351901,0.0002651711,0.000265279,0.002496036,5.691846e-7,0.000004617073,0.00001763873,0.0001327877],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6594489,"threshold_uncertainty_score":0.4604197,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2148643283","doi":"10.1056/nejmoa1207506","title":"Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy","year":2012,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4574,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; Université de Montréal","funders":"Janssen Pharmaceuticals; Chugai Pharmaceutical; Genentech; Cilag; Astellas Pharma; Teva Pharmaceutical Industries; Eisai; Sanofi; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Amgen; Pfizer; Active Biotech; Celgene; Astellas Pharma Global Development; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Enzalutamide; Prostate cancer; Medicine; Androgen receptor; Oncology; Overall survival; Internal medicine; Chemotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.0203892061612365,"gpt":0.3202014771681385,"spread":0.299812271006902,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009228829,0.0001552705,0.0004844263,0.0002440825,0.00001855721,0.000005375003,0.0000624683,0.00004018232,0.0006339602],"category_scores_gemma":[0.00006758347,0.00007725282,0.00004020365,0.0002659138,0.0001151155,0.000146046,0.000009030761,0.0003793964,0.000002917347],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001693618,"about_ca_system_score_gemma":0.0004108075,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006948122,"about_ca_topic_score_gemma":0.000182304,"domain_scores_codex":[0.9985241,0.00007985355,0.0003405785,0.00009725664,0.0005879715,0.0003702195],"domain_scores_gemma":[0.9989738,0.0001043926,0.0001428068,0.0001196719,0.00015828,0.0005010148],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02033595,0.0001805472,0.9052799,0.0000664166,0.0001747156,0.00063543,0.003169748,0.000003169324,0.003310064,0.000007203932,0.0009504225,0.06588645],"study_design_scores_gemma":[0.1696256,0.002255916,0.7827547,0.001605869,0.00020376,0.0009290634,0.0004275299,0.0000075104,0.003364467,0.00006408307,0.03861561,0.0001459133],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9719124,0.01428203,0.00001992837,0.01248875,0.0002783485,0.000251592,0.000002690949,0.000007039025,0.0007571829],"genre_scores_gemma":[0.9908887,0.003779998,0.0002146329,0.0006065289,0.003456356,0.00001060991,0.000004564921,0.00002471419,0.001013874],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1492897,"threshold_uncertainty_score":0.6941419,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2335178464","doi":"10.1056/nejm200105103441904","title":"Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis","year":2001,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Parathyroid Disorders and Treatments","field":"Medicine","cited_by":4568,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"St Joseph's Health Centre","funders":"","keywords":"Medicine; Placebo; Femoral neck; Bone mineral; Parathyroid hormone; Osteoporosis; Confidence interval; Relative risk; Urology; Bone density; Internal medicine; Surgery; Calcium","retraction":null,"screen_n_in":null,"score":{"opus":0.006138030311264983,"gpt":0.2670910643190991,"spread":0.2609530340078341,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006366105,0.0002267149,0.0008906286,0.0002767293,0.00002755013,0.000004710739,0.0000485239,0.00007275639,0.00001950794],"category_scores_gemma":[0.0001820694,0.0001184108,0.00002911099,0.0002013302,0.0001098171,0.00006871778,0.00001110794,0.0002979824,0.00000129277],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000827086,"about_ca_system_score_gemma":0.00007771692,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002317298,"about_ca_topic_score_gemma":0.00007354128,"domain_scores_codex":[0.9985898,0.000107621,0.0004406457,0.000154688,0.0004573257,0.0002499312],"domain_scores_gemma":[0.9989061,0.0002257531,0.0002932778,0.0001444181,0.00008236244,0.0003481318],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1866161,0.001552164,0.4346523,0.00008286926,0.0008768315,0.01376221,0.01016239,0.00008133015,0.2410703,0.00002295653,0.01813924,0.09298129],"study_design_scores_gemma":[0.2166845,0.1114312,0.6604823,0.0002585072,0.0004138136,0.006415452,0.0004588363,0.00001246575,0.002031965,0.0001147924,0.001542425,0.0001537521],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9871922,0.01015254,0.000008187331,0.00170573,0.00004594763,0.0002230465,0.000001705078,0.000005165387,0.0006654712],"genre_scores_gemma":[0.9975532,0.001369642,0.00009615776,0.0003482992,0.0004278409,0.000002625551,0.000005735763,0.00001541538,0.0001810606],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2390383,"threshold_uncertainty_score":0.4828652,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}